368 related articles for article (PubMed ID: 34220860)
1. Regulatory T Cells in GVHD Therapy.
Guo WW; Su XH; Wang MY; Han MZ; Feng XM; Jiang EL
Front Immunol; 2021; 12():697854. PubMed ID: 34220860
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
Front Immunol; 2020; 11():181. PubMed ID: 32117306
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
[TBL] [Abstract][Full Text] [Related]
4. CD4
Mancusi A; Piccinelli S; Velardi A; Pierini A
Front Immunol; 2019; 10():2901. PubMed ID: 31921162
[TBL] [Abstract][Full Text] [Related]
5. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.
Choi J; Ritchey J; Prior JL; Holt M; Shannon WD; Deych E; Piwnica-Worms DR; DiPersio JF
Blood; 2010 Jul; 116(1):129-39. PubMed ID: 20424188
[TBL] [Abstract][Full Text] [Related]
6. The role of regulatory T cells in graft-versus-host disease management.
Whangbo JS; Antin JH; Koreth J
Expert Rev Hematol; 2020 Feb; 13(2):141-154. PubMed ID: 31874061
[No Abstract] [Full Text] [Related]
7. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic.
Gu G; Yang JZ; Zhang JQ; Sun LX
Cell Immunol; 2019 Dec; 346():103991. PubMed ID: 31607390
[TBL] [Abstract][Full Text] [Related]
9. Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.
Yang J; Ramadan A; Reichenbach DK; Loschi M; Zhang J; Griesenauer B; Liu H; Hippen KL; Blazar BR; Paczesny S
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30694220
[TBL] [Abstract][Full Text] [Related]
10. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.
Pierini A; Strober W; Moffett C; Baker J; Nishikii H; Alvarez M; Pan Y; Schneidawind D; Meyer E; Negrin RS
Blood; 2016 Aug; 128(6):866-71. PubMed ID: 27365424
[TBL] [Abstract][Full Text] [Related]
11. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.
Ganguly S; Ross DB; Panoskaltsis-Mortari A; Kanakry CG; Blazar BR; Levy RB; Luznik L
Blood; 2014 Sep; 124(13):2131-41. PubMed ID: 25139358
[TBL] [Abstract][Full Text] [Related]
12. Mobilized Multipotent Hematopoietic Progenitors Promote Expansion and Survival of Allogeneic Tregs and Protect Against Graft Versus Host Disease.
D'Aveni M; Notarantonio AB; Agbogan VA; Bertrand A; Fouquet G; Gastineau P; Garfa-Traoré M; De Carvalho M; Hermine O; Rubio MT; Zavala F
Front Immunol; 2020; 11():607180. PubMed ID: 33643294
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine A but Not Corticosteroids Support Efficacy of
Landwehr-Kenzel S; Zobel A; Schmitt-Knosalla I; Forke A; Hoffmann H; Schmueck-Henneresse M; Klopfleisch R; Volk HD; Reinke P
Front Immunol; 2021; 12():716629. PubMed ID: 34707604
[TBL] [Abstract][Full Text] [Related]
14. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges.
Hefazi M; Bolivar-Wagers S; Blazar BR
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575843
[TBL] [Abstract][Full Text] [Related]
16. Human LAP
Wang H; Song H; Pham AV; Cooper LJ; Schulze JJ; Olek S; Tran DQ
Theranostics; 2019; 9(8):2315-2324. PubMed ID: 31149046
[TBL] [Abstract][Full Text] [Related]
17. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
18. Advances in the treatment of graft-versus-host disease with immunomodulatory cells.
Yu Q; Wang H; Zhang L; Wei W
Int Immunopharmacol; 2021 Mar; 92():107349. PubMed ID: 33486323
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease.
Prinz I; Koenecke C
Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):183-90. PubMed ID: 22476537
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD.
Landwehr-Kenzel S; Müller-Jensen L; Kuehl JS; Abou-El-Enein M; Hoffmann H; Muench S; Kaiser D; Roemhild A; von Bernuth H; Voeller M; Schmueck-Henneresse M; Gruhn B; Stervbo U; Babel N; Volk HD; Reinke P
Mol Ther; 2022 Jun; 30(6):2298-2314. PubMed ID: 35240319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
